Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 61-year-old male is currently in the medical intensive care unit undergoing treatment for a severe exacerbation of chronic obstructive pulmonary disease. He was placed on prophylactic subcutaneous unfractionated heparin upon admission. On day 6 of hospitalization, routine complete blood count reveals a platelet count of 85,000/μL85,000/\mu L, a significant decline from his admission baseline of 210,000/μL210,000/\mu L. Concurrently, he complains of new-onset right calf pain, and venous duplex ultrasonography confirms a new deep vein thrombosis. A presumptive diagnosis of heparin-induced thrombocytopenia (HIT) with thrombosis is made.

Arrange the following steps for the immediate management, subsequent monitoring, and treatment evaluation of this patient in the correct chronological sequence.

  1. 1Discontinue unfractionated heparin and all other heparin-containing products immediately.
  2. 2Initiate a continuous intravenous infusion of a non-heparin anticoagulant (e.g., argatroban).
  3. 3Monitor daily platelet counts until they recover to ≥150,000/μL\geq 150,000/\mu L or to the patient's baseline.
  4. 4Initiate overlapping therapy with a low starting dose of oral warfarin.
  5. 5Discontinue the non-heparin anticoagulant once the INR has been therapeutic for at least 48 hours.

Cevap

The correct sequence requires immediately stopping heparin, initiating a non-heparin anticoagulant, monitoring for platelet recovery, transitioning to warfarin only after platelets normalize, and discontinuing the non-heparin agent only after adequate therapeutic overlap.
The gold standard management for heparin-induced thrombocytopenia follows a strict sequence: (1) stop all heparin to halt the immune trigger, (2) provide immediate alternative systemic anticoagulation (e.g., a direct thrombin inhibitor) to manage the existing thrombosis and high prothrombotic state, (3) monitor platelets serially until they indicate the acute state is resolving (recovery to baseline or ≥150,000/μL\geq 150,000/\mu L), (4) safely introduce warfarin only when the hypercoagulable acute phase is over, and (5) ensure an adequate overlap period until the INR is completely therapeutic to avoid warfarin-induced skin necrosis.

Adım Adım Çözüm

1
Discontinue all heparin.
Halts the formation of the underlying autoantibodies against platelet factor 4 (PF4)-heparin complexes.
Continuing heparin worsens the profound prothrombotic state inherent in HIT.
2
Initiate a non-heparin anticoagulant like argatroban or bivalirudin.
Provides immediate therapeutic anticoagulation.
The patient has an active deep vein thrombosis and a high risk of systemic embolization; stopping heparin without an alternative leaves them unprotected.
3
Monitor daily platelet counts.
Establishes a timeline for resolution of the acute immune response.
The active, hypercoagulable phase of HIT is marked by thrombocytopenia. Platelet count recovery (to ≥150,000/μL\geq 150,000/\mu L) is the primary indicator that the initial massive thrombin generation has subsided.
4
Initiate warfarin at a low dose.
Begins the transition to long-term oral anticoagulation.
Warfarin must never be started while platelets are low. Warfarin causes a rapid drop in natural anticoagulant Protein C before it suppresses procoagulant factors, posing a severe risk of venous limb gangrene in active HIT.
5
Discontinue the direct thrombin inhibitor.
Completes the transition to monotherapy.
The direct thrombin inhibitor must overlap with warfarin for at least 5 days and until the INR is within the therapeutic range for 2 consecutive days, ensuring full suppression of vitamin K-dependent clotting factors.

Anahtar Kavram

Management and monitoring sequence of Heparin-Induced Thrombocytopenia (HIT)
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru